The future of recombinant coagulation factors
نویسندگان
چکیده
منابع مشابه
Recent trial results in recombinant coagulation factors for the treatment of hemophilia B
Julie Jaffray*,1 & Guy Young2 Department of Hematology/Oncology, Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, 4650 Sunset Boulevard, Mail Stop #54, Los Angeles, CA 90027, USA Department of Hematology/Oncology, Hemostasis & Thrombosis Center, Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA,...
متن کاملExtending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin.
The prophylactic treatment of haemophilia B and the management of haemophilia A or B with inhibitors demand frequent administrations of coagulation factors due to the suboptimal half-lives of the products commercially available and currently in use, e.g. recombinant factor IX (rFIX) and recombinant factor VIIa (rFVIIa), respectively. The extension of the half-lives of rFIX and rFVIIa could allo...
متن کاملCoagulation and Transfusion Medicine / RECOMBINANT FACTOR VIIA
Recombinant factor VIIa (rFVIIa) has become available for treating people with hemophilia with inhibitors who experience bleeding or require surgery. It has become apparent that rFVIIa is useful in controlling bleeding in a variety of clinical situations. This review attempts to collate and summarize the nonhemophilia applications of rFVIIa. The theoretical mechanism for the coagulation and hem...
متن کاملDifferential Consumption of Coagulation Factors
Bq II. L. NO55EL T MECHANISMS, the extrinsic and the intrinsic, have been defined whereby in vitro blood coagulation may be initiated. The extrinsic system is initiated by tissue thromboplastin which, in the presence of Factor VII and calcium, activates Factor X (Stuart-Prower factor).’5 The intrinsic system is initiated by foreign surface contact which results in sequential activation of Facto...
متن کاملCoagulation and Transfusion Medicine / UTILIZATION OF COAGULATION FACTORS
Coagulation factor replacement can effectively treat or prevent most hemophilia complications, but it is expensive. Although published data describe how to achieve therapeutic goals through cost-effective selection and dosing of replacement products, criteria are not universally known or followed. A review of our institution’s experience revealed overdosing of coagulation factors in the majorit...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thrombosis and Haemostasis
سال: 2003
ISSN: 1538-7933,1538-7836
DOI: 10.1046/j.1538-7836.2003.00196.x